Bayer CropScience Ltd Q2 FY26 – ₹15,534 million revenue, ₹2,003 million PBT, ₹90/share dividend: Agro-giant’s charm meets tax drama
1. At a Glance
Bayer CropScience Ltd — India’s pesticide powerhouse that turned farmers’ enemies into friends (and tax officers into pen pals) — delivered a Q2 FY26 revenue of ₹15,534 million with profit before tax of ₹2,003 million. PAT stood at ₹1,530 million (₹153 crore for us lazy crore-readers). For a company that claims to protect crops, it seems it also protects its dividend payout better than any crop insurance scheme — ₹90 per share interim dividend declared, totalling a solid ₹4,045 million cheque to shareholders.
With a market cap of ₹20,637 crore, ROCE of 24.8%, ROE of 20%, and P/E at 33.9x, the German-Indian hybrid continues to flex its efficiency even as its stock price (₹4,592) looks like it’s gone through a pesticide spray itself — down nearly 30% over the past year. But don’t underestimate the Bayer magic: despite declining sales (-10.6% QoQ), profit still grew 12% this quarter. That’s called “pesticide resilience” — they’ve been killing bugs for 125 years, and they won’t let market gloom bug them either.
2. Introduction
If you’ve ever wondered what happens when German engineering meets Indian monsoon uncertainty, welcome to Bayer CropScience. The company’s balance sheet is as precise as its chemical formulas, but its quarterly sales swing harder than a tractor on wet soil.
This quarter, the Agro-Goliath clocked ₹15,534 million in revenue and rewarded shareholders with another fat dividend. Because, why reinvest when you can distribute and chill? The ₹90/share dividend smells sweeter than their corn seeds, even if their sales dipped by 10.6% — perhaps the monsoon was busy taking selfies instead of raining.
Their PBT of ₹2,003 million and PAT of ₹1,530 million show the margins of a company that can laugh through import penalties, GST fines, and regulatory love letters. In fact, the ₹37.4 million GST penalty received in October 2025 was just one of many. You could say Bayer is growing both crops and compliance costs simultaneously.
Still, backed by global parent Bayer AG (71.4% holding), the company keeps innovating through science and spraying profits like fertilizers. Their portfolio covers insecticides, fungicides, herbicides, and corn seeds — or as they like to call it, “feeding India, one fine at a time.”
3. Business Model – WTF Do They Even Do?
Let’s decode the pesticide potion:
Bayer CropScience doesn’t grow crops — it makes chemicals that make sure nothing else grows on them. The business is divided into four key buckets, and each bucket is full of German discipline and Indian jugaad.
Crop Protection: The company’s bread and butter. It makes insecticides, fungicides, herbicides — the full Avengers lineup for plant safety. Its product “Vayego” (launched FY22) protects against creepy crawlies that make farmers lose sleep — though its own margins could use protection from raw material prices.
Seeds & Traits: These are their “super-seeds” — think of them as genetically superior babies of corn. Their Dekalb brand dominates the field, with hybrids like Dekalb 7204 and 9217 that promise higher yield even in drought. Bayer doesn’t sell hope — it sells yield potential in packets.
Environmental Science: The “non-farm” business. It makes chemicals to fight pests in cities, factories, and homes. Essentially, even mosquitoes have a reason to fear Bayer.
Digital Farming: This is where data meets dirt. The company offers software tools that crunch field-level data, helping farmers make decisions backed by analytics — or as Bayer puts it, “predictive pest analytics.”
With 82% of revenue from domestic agrochemicals, 11% from corn seeds, 4% from exports, and 3% from traded seeds, this is a desi-heavy business dressed in German lab coats.
4. Financials Overview
Metric (₹ million)
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue
15,534
17,380
19,150
-10.6%
-18.9%
EBITDA
2,050
1,840
3,480
+11.4%
-41.1%
PAT
1,530
1,360
2,790
+12.5%
-45.2%
EPS (₹)
33.98
30.33
62.01
+12.0%
-45.2%
So yes, sales fell off a cliff but profits somehow held strong — possibly because Bayer manages costs like a true German engineer. The EBITDA margin stands around 13%, down from the 18–19% highs of FY23.
The company’s annualized EPS = ₹33.98 × 4 = ₹135.9, which matches the screener-reported EPS. At the CMP of ₹4,592, P/E = 33.8x, which is high enough to qualify as “organic premium fertilizer.”
5. Valuation Discussion – Fair Value Range
Let’s get nerdy.
a) P/E Method Industry average P/E = 28.4 Company P/E = 33.9 EPS = ₹135
Fair Value (low) = 28.4 × 135 = ₹3,834
Fair Value (high) = 33.9 × 135 = ₹4,576
b) EV/EBITDA Method EV/EBITDA = 23.7 EBITDA (TTM) = ₹7,450 million = ₹745 crore EV = ₹20,073 crore So fair EV range if sector median (18–22x): = ₹745 × 18 = ₹13,410 crore (lower) = ₹745 × 22 = ₹16,390 crore (upper) Per share range ≈ ₹3,300–₹4,000
c) Simplified DCF Assume free cash flow of ₹550 crore (5-year avg), 6% growth, 11% discount rate → intrinsic value ≈ ₹4,100–₹4,500
📊 Fair Value Range (Educational): ₹3,800 – ₹4,500
Disclaimer: This fair value range is for educational purposes only and not investment advice.
6. What’s Cooking – News, Triggers, Drama
Oh boy, Bayer CropScience’s newsfeed this year could make a legal thriller.
The Good:
Declared a juicy ₹90/share interim dividend, record date November 14, 2025. Because nothing says “confidence” like paying shareholders when GST officers are calling.
H1 FY26 revenue at ₹34,680 million and PBT ₹5,355 million — a strong half despite tough weather and pricing headwinds.
